SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SWOG | S1827-SCLC, MRI Surveillance +/- PCI | 1 | Y | 1 PCI + MRI brain surveillance | 668 | 126 | 32 | 15 | 7 | 2 | 1 | 05/04/2020 | 344 | 131 |
2 MRI brain surveillance | 125 | 34 | 12 | 8 | 2 | 1 | ||||||||
251 | 66 | 27 | 15 | 4 | 2 | |||||||||
S1933-NSCLC, Stg II-III, RT + Atezo | 1 | Y | 1 Hypofractionated Radiotherapy | 47 | 40 | 8 | 2 | 1 | 1 | 1 | 01/13/2021 | 105 | 39 | |
40 | 8 | 2 | 1 | 1 | 1 | |||||||||
2 | Y | 2 Atezolizumab | 31 | 7 | 2 | 0 | 0 | 0 | 01/13/2021 | |||||
31 | 7 | 2 | 0 | 0 | 0 | |||||||||
S2302-NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC | 1 | N | 1 Standard of Care (Inv. Choice) | 800 | 419 | 292 | 161 | 95 | 41 | 18 | 03/14/2023 | 487 | 200 | |
2 Ramucirumab + Pembrolizumab | 419 | 296 | 158 | 94 | 39 | 11 | ||||||||
838 | 588 | 319 | 189 | 80 | 29 | |||||||||
Yes | A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO | 1 | E | Total Registrations | 87 | 20 | 11 | 3 | 0 | 0 | 10/20/2020 | 417 | 172 | |
87 | 20 | 11 | 3 | 0 | 0 | |||||||||
A151216-ALCHEMIST0 - screening | 1 | E | Total Registrations | 985 | 20 | 10 | 3 | 2 | 0 | 12/16/2014 | 516 | 236 | ||
985 | 20 | 10 | 3 | 2 | 0 | |||||||||
EA5162-NSCLC,StgIV/IIB,EGFR exon20 insertion,AZD9291 | 1 | E | Total Registrations | 1 | 0 | 0 | 0 | 0 | 0 | 08/23/2023 | 85 | 41 | ||
1 | 0 | 0 | 0 | 0 | 0 | |||||||||
EA5182-NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 | 1 | E | Total Registrations | 21 | 11 | 4 | 1 | 0 | 0 | 04/28/2021 | 181 | 81 | ||
21 | 11 | 4 | 1 | 0 | 0 | |||||||||
EA5221-Lung, Advanced NSCLC, ChemoImmuno/Immuno | 1 | E | Total Registrations | 1 | 1 | 1 | 0 | 0 | 0 | 08/07/2024 | 167 | 67 | ||
1 | 1 | 1 | 0 | 0 | 0 | |||||||||
2 | E | Total Registrations | 1 | 1 | 1 | 0 | 0 | 0 | 08/07/2024 | |||||
1 | 1 | 1 | 0 | 0 | 0 | |||||||||
NRGLU008-Lung NSCL, StgII-III, StereoBodyRad/MedChemo | 1 | E | Total Registrations | 2 | 2 | 1 | 0 | 0 | 0 | 01/26/2024 | 269 | 102 | ||
2 | 2 | 1 | 0 | 0 | 0 | |||||||||
No | A082002-Lung, Adv, Systemic Tx +/- SBRT | 1 | E | Total Registrations | 4 | 1 | 0 | 0 | 0 | 0 | 10/12/2022 | 223 | 72 | |
4 | 1 | 0 | 0 | 0 | 0 | |||||||||
A151216-ALCHEMIST0 - screening | 0 | E | Total Registrations | 999 | 20 | 9 | 3 | 2 | 0 | 12/16/2014 | 516 | 236 | ||
999 | 20 | 9 | 3 | 2 | 0 | |||||||||
OPEN | Study | Date Closed |
Reg. | Arm | Total Regs |
Regs Last 30 Days |
Regs Last 7 Days |
---|---|---|---|---|---|---|---|
N | S2302-NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC | 20-Dec-24 | 1 | 1 Standard of Care (Inv. Choice) | 419 | 41 | 18 |
2 Ramucirumab + Pembrolizumab | 419 | 39 | 11 |